[Lab] QYB orfo — Medutest came back 99.3% against a claimed 99.0%
Short version of the title, which is already short: QYB orfo — Medutest came back 99.3% against a claimed 99.0%. Longer version underneath.
Numbers, in the order they matter: 99.3% and 99.0%.
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
Ask me anything specific. Anything general I will probably get wrong.
- QYQYB source pageChinaPeptides Co., Ltd. (QYAOBIO) · Shanghai · 93% here, rank 11 · shop at qyaobiopeptides.com →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Which programme and which readout are you quoting?
Which programme and which readout are you quoting?
Adding the standing caveat — unapproved, and research material is not for human use.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Left up. It is careful about what is peptide and what is not, which is more than most threads here manage.
Is that from the publication or the press release?
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
nothing containing this is approved anywhere and research material is not for human use
identity testing on a small molecule is a different analytical problem
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
nothing containing this is approved anywhere yet
Agreed — non-peptide is the fact that everything else follows from, including the manufacturing and the analytics.
oral and non-peptide is the whole engineering story
That is a phase 2 result being quoted as though the programme had reported.
Daily dosing, so what does the exposure profile look like across the day?
Why "oral" is doing two completely different jobs in the sentences people write here.
Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.
The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.
the boards keep comparing it to injectables at matched doses, which is meaningless
What analytical method was used — this is not the usual peptide assay question?
- 1Daily rather than weekly sounds trivial until you think about what a missed…9 comments in this branch · started by u/certified_reference
- 2Oral semaglutide is a peptide co-formulated with an absorption enhancer and…6 comments in this branch · started by u/joaquin_trevino